PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival
- 20 December 2022
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 23 (3) , e131-e139
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patientOncotarget, 2016
- The assessment of HER2 status in breast cancer: the past, the present, and the futurePathology International, 2016
- Association of genetic polymorphisms in PTEN and additional gene-gene interaction with risk of esophageal squamous cell carcinoma in Chinese Han populationDiseases of the Esophagus, 2015
- PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancersOncogene, 2015
- Resistance to Anti-HER2 Therapies in Breast CancerAmerican Society of Clinical Oncology Educational Book, 2015
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsMolecular Biology International, 2014
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusJNCI: Journal of the National Cancer Institute, 2014
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancerBreast Cancer Research and Treatment, 2011
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004